Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
about
Atypical hemolytic uremic syndromeSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesHypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerChronic VEGF blockade worsens glomerular injury in the remnant kidney modelVascular endothelial growth factor as an anti-angiogenic target for cancer therapyMultifaceted hemolytic uremic syndrome in pediatrics.Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Adrenomedullin as a therapeutic target in angiogenesis.Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular SystemAnti-VEGF Cancer Therapy in Nephrology PracticeBevacizumab in the treatment of ovarian cancer.Nephrotoxicity of recent anti-cancer agents.Progressive bevacizumab-associated renal thrombotic microangiopathy.Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Management of antiangiogenic therapy-induced hypertension.Diabetic angiopathy and angiogenic defects.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyeNOS deficiency predisposes podocytes to injury in diabetes.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.MicroRNA control of vascular endothelial growth factor signaling output during vascular development.Minimal change disease onset observed after bevacizumab administration.Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.Antiangiogenic drugs in ovarian cancer.Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imagingRole of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 modelManagement of hypertension in angiogenesis inhibitor-treated patients.Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.Targeted therapy: comprehensive review.Brivanib alaninate for cancer.Bevacizumab-induced hypertension: pathogenesis and management.Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.Panitumumab : leading to better overall survival in metastatic colorectal cancer?Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.Inhibition of the VEGF signalling pathway and glomerular disorders.Renal effects of targeted anticancer therapies.Axitinib in metastatic renal cell carcinoma.
P2860
Q21202864-6D036F8F-CF91-4E5A-9FF5-B0D83B4E7485Q21261307-94F557F4-0385-4C69-9130-3678978E3E0FQ24595773-5AC58BBA-9378-4BB8-9537-453E34B3A124Q28728129-A875E3F1-0A85-43E7-839E-50D5A16B1A05Q30455612-EDBCC0B4-FE6F-46A4-AB18-20067F52E53CQ33405452-4D86E494-24F3-4A12-A86E-3337F70FCF6EQ33430382-36B6D666-CFF7-4320-B93E-D1819E6C8375Q33433070-881CB688-D82D-4872-98DB-A9C4A92BE068Q33684042-21A63E3D-2868-4CFB-86AD-71B08F0BA7F0Q33693793-7CDB6655-0FF2-418E-9C5A-DED4EADCF07AQ33710562-138BD7F9-CB0C-440D-A08A-E4D29D861AF3Q33814199-F45E1A06-93D4-46CB-BF50-EF14718FFF16Q34152125-DA16529B-9F22-4457-81E5-5D4D1185C9D6Q34605261-2606C098-CB6D-4ECC-B8B2-4181BA475FE0Q35310741-EC723B39-A10B-496A-8447-4E57AE1513FCQ35574176-F23582B1-90B1-46F0-8E2B-24A50A611F02Q35902676-0DA71F10-96E6-4BC2-B817-993F1D3FD5A5Q36170252-2E0609EF-741D-4959-A09A-3433A823AEBFQ36301365-1B2791FB-2861-4B41-8850-D9CE039BADD5Q36318627-2BDB7AF6-78B7-4547-8637-2A22E2053900Q36352132-F6E77CA6-901F-4F80-87F6-95D8342C01C6Q36526512-C0456E48-0B5B-41E7-B94E-A96B8B617160Q36554547-E74AAA2B-1091-48FF-87D8-1E0F15F19E0DQ36689167-B8C6B6FD-FB58-44B2-A321-CDEF6A50B575Q37039058-125BCB27-668D-4E0E-9084-5CD30E24808CQ37080913-4D43DC26-F54F-40B9-80E9-148CE8BD82BBQ37126776-DDB988DC-E588-4EDB-AD8F-68C24A482799Q37154812-98B18CC6-9D2F-418D-B922-EA51C89663D3Q37245368-A081F012-98E7-4C88-B7C3-9D64B9EA7E8CQ37371312-03A10736-3A3C-4475-AE20-891B4EBDAC9FQ37387829-1F3A5A05-E332-4267-8DB4-2325F0D873EEQ37396743-4506926E-4409-439E-BB74-1E793F7BB7B6Q37851518-A671B172-FC33-4315-8781-A7BABB20BF80Q37882684-6DC2686E-AA1F-4F2E-ACC5-E7464CCD85ADQ37917796-634D8489-C3E2-4C77-9D8D-99C816499684Q38193195-A8B73CAA-0090-4AEF-8B3B-C9CA1026168AQ38225636-3E635DA9-1D99-4B0C-846C-A785C0B3CFD3Q38284055-85B2144C-8FA6-45AF-9835-A704DF20335DQ38367168-A802077D-B0E2-4605-BD1D-78B9150E16D0Q38439661-59DA4674-D7A1-4A2D-AE98-B1948EA338BC
P2860
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
@en
type
label
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
@en
prefLabel
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
@en
P2093
P1476
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
@en
P2093
Alain Baumelou
Bertrand Billemont
Gilbert Deray
Hassane Izzedine
P304
P356
10.1053/J.AJKD.2007.04.025
P50
P577
2007-08-01T00:00:00Z